Steven Mark Sorscher, MD

About Me

Education: BS, Yale University, 1981; MD, University of Michigan - Ann Arbor, 1985
Residency: Internal Medicine, University Michigan Affiliated Hospitals, 1988
Fellowship: Hematology And Oncology, University of California - San Diego, 1991
Board Certifications: American Board of Internal Medicine, Internal Medicine; American Board of Internal Medicine, Medical Oncology
Positions: Professor, Hematology and Oncology
Departments and Affiliations: Hematology and Oncology

Analytical Validity and Clinical Utility of Tumor Biomarkers. Sorscher S. JAMA Oncol. 2018 Oct; 4(10):1432.
Clarification of the FDA Accelerated Agnostic Approval of Pembrolizumab and the Opportunities Arising From the Required Confirmatory Studies. Sorscher S. JAMA Oncol. 2018 Sep; 4(9):1299-1300.
Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?. Sorscher S. Curr Probl Cancer. 2018 11; 42(6):601-604.
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations. Sorscher S. Oncologist. 2018 Nov; 23(11):1266-1268.
Ascertainment Bias and Estimating Penetrance. Sorscher S. JAMA Oncol. 2018 Apr; 4(4):587.

View More Publications